Background: Dermatofibroma usually occurs on the extremities or trunk as a common and benign skin tumor. The identification of typical dermatofibroma is uncomplicated, although it can be challenge due to its wide range of presentations and histological variations. Objective: This study was undertaken to evaluate the clinical and histopathological？characteristics of 147 Cases of Dermatofibroma. Methods: This is a retrospective study of 147 biopsy specimens of 124 patients who were diagnosed with dermatofibroma in the Department of Dermatology and the Department of Pathology at the Seventh Affiliated Hospital of Sun Yat-sen University？between January 2009 and April 2024. All case were retrieved from the saved medical records. Results: Ages of the 124 Dermatofibroma-affected individuals ranged from 11 to 61 years with a male-to-female ratio of 1:1.7. Over 80% of the case occurred between the ages of 20 and 49 years, 61.9% of the lesions were found on the extremities. The duration of the cases varied from 17 days to 30 years and half of lesions (58.2%) persisted for less than two years. Over 60% of the lesions were found on the extremities. The diameter of the tumors ranged between 0.3 cm and 5 cm, with most tumors measuring less than or equal to 2 cm (85.00%). Cutaneous masses or dermatofibroma was the most common clinical diagnosis. Most tumors (79.6%) were asymptomatic. Cutaneous masses or dermatofibroma was the most common clinical diagnosis. Prior to the surgical procedure, 57 cases were suspected to be “DF”, 55 cases were suspected to be “cutaneous masses”. Immunohistochemical staining revealed positive expression of SMA, while the negative rate of CD34 was found to be 66.67%. No diffuse CD34 positivity was observed in all tumors. Conclusion: Variations in clinical features, pathological manifestations, and immunohistochemical results of DF pose challenges for accurate diagnosis. A comprehensive understanding of its clinical and pathological characteristics is crucial for precise identification. Incorporating immunohistochemical analysis can help prevent misdiagnosis.
References
[1]
Rahbari, H. and Mehregan, A.H. (1985) Adnexal Displacement and Regression in Association with Histiocytoma (Dermatofibroma). Journal of Cutaneous Pathology, 12, 94-102. https://doi.org/10.1111/j.1600-0560.1985.tb01608.x
[2]
Han, T.Y., Chang, H.S., Lee, J.H.K., Lee, W. and Son, S. (2011) A Clinical and Histopathological Study of 122 Cases of Dermatofibroma (Benign Fibrous Histiocytoma). Annals of Dermatology, 23, 185-192. https://doi.org/10.5021/ad.2011.23.2.185
[3]
Poissonnet, C.M., Burdi, A.R. and Bookstein, F.L. (1983) Growth and Development of Human Adipose Tissue during Early Gestation. Early Human Development, 8, 1-11. https://doi.org/10.1016/0378-3782(83)90028-2
[4]
Hügel, H. (2006) Fibrohistiocytic Skin Tumors. Journal der DeutschenDermatologischen Gesellschaft, 4, 544-554. https://doi.org/10.1111/j.1610-0387.2006.06021.x
[5]
Hui, P., Glusac, E.J., Sinard, J.H. and Perkins, A.S. (2002) Clonal Analysis of Cutaneous Fibrous Histiocytoma (Dermatofibroma). Journal of Cutaneous Pathology, 29, 385-389. https://doi.org/10.1034/j.1600-0560.2002.290701.x
[6]
Yazici, A., Baz, K., Ikizoglu, G., Koca, A., Kokturk, A. and Apa, D. (2005) Familial Eruptive Dermatofibromas in Atopic Dermatitis. Journal of the European Academy of Dermatology and Venereology, 20, 90-92. https://doi.org/10.1111/j.1468-3083.2005.01357.x
[7]
Chen, T., Kuo, T. and Chan, H. (2000) Dermatofibroma Is a Clonal Proliferative Disease. Journal of Cutaneous Pathology, 27, 36-39. https://doi.org/10.1034/j.1600-0560.2000.027001036.x
[8]
Zelger, B.G. and Zelger, B. (2001) Dermatofibroma (Fibrous Histiocytoma): An Inflammatory or Neoplastic Disorder? Histopathology, 38, 379-381. https://doi.org/10.1046/j.1365-2559.2001.01131-2.x
[9]
Niemi, K.M. (1970) The Benign Fibrohistiocytic Tumours of the Skin. Acta Dermato-Venereologica, 50, 1-6.
[10]
Tsunemi, Y., Tada, Y., Saeki, H., Ihn, H. and Tamaki, K. (2004) Multiple Dermatofibromas in a Patient with Systemic Lupus Erythematosus and Sjogren’s Syndrome. Clinical and Experimental Dermatology, 29, 483-485. https://doi.org/10.1111/j.1365-2230.2004.01574.x
[11]
Chan, I., Robson, A. and Mellerio, J.E. (2005) Multiple Dermatofibromas Associated with Lupus Profundus. Clinical and Experimental Dermatology, 30, 128-130. https://doi.org/10.1111/j.1365-2230.2004.01663.x
[12]
Zaccaria, E., Rebora, A. and Rongioletti, F. (2008) Multiple Eruptive Dermatofibromas and Immunosuppression: Report of Two Cases and Review of the Literature. International Journal of Dermatology, 47, 723-727. https://doi.org/10.1111/j.1365-4632.2008.03575.x
[13]
An, İ. (2018) Multiple Eruptive Dermatofibromas in a Patient with Systemic Lupus Erythematosus Treated with Methylprednisolone. Archives of Rheumatology, 33, 236-237. https://doi.org/10.5606/archrheumatol.2018.6569
[14]
Queirós, C., Uva, L., Soares de Almeida, L. and Filipe, P. (2019) Multiple Eruptive Dermatofibromas Associated with Pregnancy—A Case and Literature Review. Dermatology Online Journal, 25, Article 12. https://doi.org/10.5070/d3255044074
[15]
Gaufin, M., Michaelis, T. and Duffy, K. (2019) Cellular Dermatofibroma: Clinicopathologic Review of 218 Cases of Cellular Dermatofibroma to Determine the Clinical Recurrence Rate. Dermatologic Surgery, 45, 1359-1364. https://doi.org/10.1097/dss.0000000000001833
[16]
Guillou, L., Gebhard, S., Salmeron, M. and Coindre, J. (2000) Metastasizing Fibrous Histiocytoma of the Skin: A Clinicopathologic and Immunohistochemical Analysis of Three Cases. Modern Pathology, 13, 654-660. https://doi.org/10.1038/modpathol.3880115
[17]
Doyle, L.A. and Fletcher, C.D.M. (2013) Metastasizing “Benign” Cutaneous Fibrous Histiocytoma: A Clinicopathologic Analysis of 16 Cases. American Journal of Surgical Pathology, 37, 484-495. https://doi.org/10.1097/pas.0b013e31827070d4
[18]
Orzan, O.A., Dorobanțu, A.M., Gurău, C.D., Ali, S., Mihai, M.M., Popa, L.G., et al. (2023) Challenging Patterns of Atypical Dermatofibromas and Promising Diagnostic Tools for Differential Diagnosis of Malignant Lesions. Diagnostics, 13, Article 671. https://doi.org/10.3390/diagnostics13040671
[19]
Mentzel, T., Wiesner, T., Cerroni, L., Hantschke, M., Kutzner, H., Rütten, A., et al. (2013) Malignant Dermatofibroma: Clinicopathological, Immunohistochemical, and Molecular Analysis of Seven Cases. Modern Pathology, 26, 256-267. https://doi.org/10.1038/modpathol.2012.157
[20]
Yanagisawa, A. and Okada, H. (2008) Nodular Fasciitis with Degeneration and Regression. Journal of Craniofacial Surgery, 19, 1167-1170. https://doi.org/10.1097/scs.0b013e318176ac1a
[21]
Vyas, T., Bullock, M.J., Hart, R.D., Trites, J.R. and Taylor, S.M. (2008) Nodular Fasciitis of the Zygoma: A Case Report. Canadian Journal of Plastic Surgery, 16, 241-243. https://doi.org/10.1177/229255030801600405
[22]
Amary, M.F., Ye, H., Berisha, F., Tirabosco, R., Presneau, N. and Flanagan, A.M. (2013) Detection of USP6 Gene Rearrangement in Nodular Fasciitis: An Important Diagnostic Tool. VirchowsArchiv, 463, 97-98. https://doi.org/10.1007/s00428-013-1418-0
[23]
Shin, C., Low, I., Ng, D., Oei, P., Miles, C. and Symmans, P. (2016) USP6 Gene Rearrangement in Nodular Fasciitis and Histological Mimics. Histopathology, 69, 784-791. https://doi.org/10.1111/his.13011
[24]
Emory, T.S., Scheithauer, B.W., Hirose, T., Wood, M., Onofrio, B.M. and Jenkins, R.B. (1995) Intraneural Perineurioma: A Clonal Neoplasm Associated with Abnormalities of Chromosome 22. American Journal of Clinical Pathology, 103, 696-704. https://doi.org/10.1093/ajcp/103.6.696
[25]
Brock, J.E., Perez-Atayde, A.R., Kozakewich, H.P.W., Richkind, K.E., Fletcher, J.A. and Vargas, S.O. (2005) Cytogenetic Aberrations in Perineurioma: Variation with Subtype. American Journal of Surgical Pathology, 29, 1164-1169. https://doi.org/10.1097/01.pas.0000158397.65190.9f
[26]
Ko, E., McNamara, K., Ditty, D. and Alawi, F. (2020) Intraneural Perineurioma of the Mandible: Case Series of a Rare Entity. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 130, 428-432. https://doi.org/10.1016/j.oooo.2020.07.004
[27]
Hernández-Martín, A. and Duat-Rodríguez, A. (2016) Neurofibromatosis tipo 1: Más que manchas café con leche, efélides y neurofibromas. Parte II. Actualización sobre otras manifestaciones cutáneas características de la enfermedad. NF1 y cáncer. Actas Dermo-Sifiliográficas, 107, 465-473. https://doi.org/10.1016/j.ad.2016.01.009
[28]
Linos, K., Kozel, J.A., Hurley, M.Y. and Andea, A.A. (2018) Review of the Medical Literature and Assessment of Current Utilization Patterns Regarding the Use of Two Common Fluorescence in Situ Hybridization Assays in the Diagnosis of Dermatofibrosarcoma Protuberans and Clear Cell Sarcoma. Journal of Cutaneous Pathology, 45, 905-913. https://doi.org/10.1111/cup.13345
[29]
Lassana, F.M., Coumba, B.Y., Daour, T.E.H. and Aurore, S.A. (2024) Dermatofibrosarcoma Protuberans of the Breast: A Rare Localization. Advances in Breast Cancer Research, 13, 36-42. https://doi.org/10.4236/abcr.2024.133004
[30]
Criscione, V.D. and Weinstock, M.A. (2007) Descriptive Epidemiology of Dermatofibrosarcoma Protuberans in the United States, 1973 to 2002. Journal of the American Academy of Dermatology, 56, 968-973. https://doi.org/10.1016/j.jaad.2006.09.006
[31]
Reha, J. and Katz, S.C. (2016) Dermatofibrosarcoma Protuberans. Surgical Clinics of North America, 96, 1031-1046. https://doi.org/10.1016/j.suc.2016.05.006
[32]
Acosta, A.E. and Vélez, C.S. (2017) Dermatofibrosarcoma Protuberans. Current Treatment Options in Oncology, 18, Article No. 56. https://doi.org/10.1007/s11864-017-0498-5
[33]
Liang, C.A., Jambusaria-Pahlajani, A., Karia, P.S., Elenitsas, R., Zhang, P.D. and Schmults, C.D. (2014) A Systematic Review of Outcome Data for Dermatofibrosarcoma Protuberans with and without Fibrosarcomatous Change. Journal of the American Academy of Dermatology, 71, 781-786. https://doi.org/10.1016/j.jaad.2014.03.018
[34]
Spiller, W.F. and Spiller, R.F. (1975) Cryosurgery in Dermatologic Office Practice. Southern Medical Journal, 68, 157-160. https://doi.org/10.1097/00007611-197502000-00009
[35]
Wetmore, S.J. (1999) Cryosurgery for Common Skin Lesions. Treatment in Family Physicians’ Offices. Canadian Family Physician, 45, 964-974.
